Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies

Phase 1Investigational antibodies targeting orthopoxvirusesPositive

AI Analysis

Summary

Evotec Biologics has initiated a first-in-human Phase 1 clinical study for investigational antibodies targeting orthopoxviruses under the U.S. Department of War Accelerated Antibodies Program. The program aims to develop countermeasures against orthopoxviruses identified as a high-priority biological threat.

Clinical Trial Data

Phase

Phase 1

Outcome Details

First-in-human Phase 1 study initiated

Importance:6/10

Sentiment:

0.60

orthopoxvirusantibodiesclinical trialPhase 1government partnershipinfectious disease

Related Companies

$EVO

Read the original article

Published by PR Newswire Pharma on September 9, 2026 6:00 AM

Read Original